• Wed news: Medicare $2 generics. Biogen’s high-dose Spinraza. Roche breast cancer trial. Lilly’s unique AI deal. Sage Alzheimer’s fail. See more on our front page

Layoffs Coming

















Derm is struggling? Didn't they just launch a JAK?

you call that a launch? It’s actually pathetic. JAK numbers are horrible and Eucrisa numbers have been in decline for a while…if you decided to stick it out for a pink slip and a package then you’re well on your way to making that dream a reality, and likely sooner than you think. Hope you have a backup plan!
 




Similar threads